A program focused on advancing the clinical development of gene therapy and cell therapy programs, including HF10, NY-ESO-1・siTCR and CD19・CAR, with the aim of early commercialization. Even after adopting a policy to discontinue in-house clinical development, the company will continue validating related genetic analysis and drug discovery platform technologies, as well as certain projects.